Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The company will provide comprehensive response to USFDA for the observations
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Subscribe To Our Newsletter & Stay Updated